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Two galactosyl derivatives of [DMet2,Pro5] enkephalin-
amide (compound 1), namely [DMet2,Pro5] enkephalin
[N'5_-f3--galactopyranosyl] amide (compound 2) and
O"5-(j--galactopyranosyl) [DMet2,Hyp ] enkephalin-
amide (compound 3) have been synthesized. Such
glycosylpeptides have been shown to be extremely potent
analgesic agonists. The conformational analysis of these
three compounds in DMSOd solution has been carried
out using two-dimensional NMR methods. Both the
parent compound (1) and the flN-galactosyl derivative (2)
show similar NMR parameters which are consistent with
fairly rigid fl-strands at both the N-terminus and
C-terminus, connected by a glycine residue that displays
a mixture between multiple conformational states. Thus,
although the ,BN-galactosyl derivative (2) has been shown
to be significantly more potent than the parent compound
(1) in the tail immersion and paw pressure tests of
analgesia, no correlation can be established between the
conformation of (1) and (2) in DMSO and the difference
in analgesic activity. In contrast, important confor-
mational differences with respect to (1) and (2) have been
detected in the l0O-galactosyl derivative (3). In this case,
only one of the likely conformations for (1) and (2) are
consistent with the experimental data. These data show
that the position of the galactose residue in compound
(3) causes Gly3 to loose flexibility leading to a more rigid
folded conformation. Such a change in conformation
could be related to the difference in analgesic activity
between (2) and (3).
Key words: glycosyl peptides/enkephalin analogues/analgesic
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Introduction
There is increasing evidence that the carbohydrate moieties
of glycopeptides and glycoproteins play an important role
in their biological activity and selectivity. It has become
widely accepted that exposed sugar residues of glycoproteins
or glycolipids serve as determinants for receptor recognition.
In this sense, carbohydrate residues linked to proteins have
been reported to be involved in such crucial processes as
cell growth and cell differentiation (Olden et al., 1985) and
infection (Ofek et al., 1978). It has also been found that
different mammalian receptors exhibit a considerable and
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specific affinity for either D-glucose or D-galactose
containing glycoproteins (Ashwell and Harford, 1982;
Lunney and Ashwell, 1976). Considering that this selection
mechanism might hold for many analogous glycoproteins
and for mammals in general (Ashwell and Morell, 1974),
the incorporation of sugar moieties could give an improve-
ment of the selectivity of pharmaceuticals towards different
receptors.
In earlier papers we reported a considerable increase in
analgesic activity after incorporation of D-glucose and
D-galactose residues into enkephalins (Torres et al., 1988;
Garcia-Anton et al., 1987). These results encouraged us to
further investigate the influence of the sugar moieties in the
activity and selectivity of such glycopeptides. Thus, we have
incorporated the same sugar moieties into different positions
in the parent peptide.
In the present work we describe the synthesis of a series
of potent analgesic galactosyl enkephalins. For comparative
purposes we selected the same parent compound that we used
before (Torres et al., 1988; Garcia-Ant6n et al., 1987),
[DMet2,Pro5] enkephalinamide (Bajusz et al., 1977), (com-
pound 1). This enkephalin analogue is a potent it-selective
agonist (Shaw and Turnbull, 1978) that shows a selectivity
ratio l/6 = 30. The galactosyl moieties have been incor-
porated into the fifth amino acid both via a fN-glycosyl
linkage between the C-terminal proline and ,B-D-
galactopyranosylamine to give [DMet2,Pro5] enkephalin
[Nl 5-0-D-galactopyranosyl] amide (compound 2) and via
flO-glycosyl bond formation between the hydroxyl group of
hydroxyproline and f3-D-galactouyranose to give 0 '5-(3-D-
galactopyranosyl) [DMet2,Hyp ] enkephalinamide (com-
pound 3). The schematic structures of both the N- and
0-glycosyl enkephalin derivatives, as well as the parent com-
pound, are shown in Figure 1.
The in vivo analgesic activity of these three compounds
has been studied. Even though this material is due to be
published elsewhere, we wish to summarize here some
significant data related to the NMR data. The 0-galactosyl
derivative (3) is the most active of these analogues and one
of the most potent in vivo opioid peptide agonists synthesized
up to now. This galactosyl analogue has proved to be
>50 000-fold more potent than morphine and 1000-fold
more potent than the parent compound (1) in rats, in both
the tail immersion and paw pressure tests of analgesia after
intraventricular administration (10 animals) (Rodriguez
et al., 1989). Compound (2) is also a potent analogue but
- 10 times less potent than compound (3) in the same test
of analgesia (Rodriguez et al., 1989). These significant
results have led us to question whether any conformational
changes could be related to such an important increase in
analgesic activity induced by the sugar moieties of such
glycosyl enkephalins.
The conformational properties of both naturally occurring
enkephalins and their synthetic analogues have been widely
studied by many authors using spectroscopic methods, X-ray
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* Prepared following the stepwise liquid phase procedure by usinq
mixed anhydrides (Isobutylchloroformate) as activated N-protected
amino acids (Torres et al, 1988).
Fig. 2. Synthesis of compounds (2) and (3). Glycosylation strategies.
O'-5- (B-D-galactopyranosyl)[D-Met2,Hyp'] enkephalin amide (3)
Fig. 1. Schematic structures of the parent compound (1) and the
galactosyl derivatives (2) and (3).
crystallography and energy calculations (for reviews see
Rapaka et al., 1986; Schiller, 1984). Theoretical studies on
low energy conformations of enkephalins indicate that both
,B-turns and extended forms are possible stable conformations
in equilibrium (Loew and Burt, 1978; De Coen et al., 1977;
Wijne, 1980; Manavalan and Momany, 1981; Paine and
Scheraga, 1985, 1986; Purisima and Scheraga, 1987).
Experimental methods have also led to many different
conclusions. Thus, several authors have detected folded
conformations of enkephalins in DMSO or water solutions,
mainly by NMR measurements (Garbay-Jaureguiberry et al.,
1976, 1980; Jones et al., 1976; Momany, 1977), whereas
some other authors find no proof for the existence of stable
folded conformations in solution for such small peptides,
neither from NMR data (Motta et al., 1987; Higashijima
et al., 1979) nor from UV and circular dicroism data (Spirtes
et al., 1978). Nevertheless, Highashijima et al. (1979) pointed
out the importance of ionization in the resulting conforma-
tion. They suggested that folded dipolar forms could be
stabilized by head to tail interactions between the two charged
ends of the peptide.
Most of these conformational analyses of enkephalins were
based on ID NMR measurements. For many years, the
presence of folded conformations in solution has been mainly
supported by both low temperature coefficients of NH
chemical shifts and coupling constants. Modern NMR
techniques allow the measurement of other spectroscopical
parameters, in particular nuclear Overhauser effects (NOEs),
which lead to more unequivocal conclusions. Such techniques
have been successfully used in the determination of protein
structures (Wuthrich, 1986). However, two problems
hamper the application of NOE techniques to peptides of
the size of enkephalins. Firstly their unfavourable co0ro
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values make it difficult to detect NOEs. This problem can
be avoided either by changing the magnetic field strength
or by increasing the solvent viscosity at low temperatures
(Motta et al., 1988). A different approach is to measure the
NOEs in the rotating frame, for which no wo0o condition
yields zero NOEs (Bothner-By et al., 1984). Secondly, the
flexibility of small linear peptides causes them to show a
wide number of conformations in solution and averages the
measured conformation-dependent parameters, NOEs in
particular (Jardetzky, 1980; Kessler et al., 1988). In the
present work we describe the conformational study of the
new series of galactosyl enkephalins in DMSO-d6 solutions
using NOESY and ROESY experiments.
Results
Synthesis
Compounds (2) and (3) have been synthesized following
different strategies. The best reaction pathways among those
tested are shown in Figure 2. The preparation of (2) includes
the ,BN-glycosylation of the pentapeptide tBoc-Tyr-DMet-
Gly-Phe-Pro-OH (63% yield) (Figure 2a) whereas
compound (3) was obtained by previous 0O-glycosylation
of protected hydroxyproline and subsequent incorporation
of this galactosyl amino acid, after saponification, to the rest
of the peptide fragment (Figure 2b). In this case two
hydroxyl protecting groups on the sugar moiety have been
used. The best chemical yields were obtained by using
acetylated sugars instead of the bulkier benzyl derivatives.
Thus in the coupling between 0-(2,3,4,6-tetra-O-acetyl-f-
D-galactopyranosyl) hydroxyproline methyl ester and tBoc-
Tyr-DMet-Gly -Phe-OH 75% yield was achieved
compared to 29% using 0'-(2,3,4,6-tetra-O-benzyl-f-D-
galactopyranosyl) hydroxyproline methyl ester.
Conformational analysis
The conformation of (1), (2) and (3) in DMSO-d6 was
studied by 'H-NMR at 270 MHz. All the signals were
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Table I. The 270 MHz 'H-chemical shifts of (1), (2) and (3) in
DMSO-d6
Compound
(1) (2) (3)
Tyr NH3'
ci
/2
ortho H
meta H
DMet NH
a
02
YI,2
S-CH3
Gly NH
a1
a2
Phe NH
a
02
aromatic H
Pro/Hyp ca
02
72
62
_a
3.92
2.82
2.82
6.96
6.62
8.57
4.25
1.70
1.55
2.15
1.95
8.13
3.65
3.50
8.19
4.65
3.00
2.68
7.15-7.27
4.18
1.92
1.74
1.78
1.78
3.56
3.56
galac NH
HI
H2
H3
H4
H5
H6
-a
3.98
2.82
2.82
6.96
6.65
8.62
4.26
1.72
1.58
2.18
1.98
8.20
3.68
3.55
8.12
4.67
2.98
2.73
7.15-7.27
4.31
2.00
1.94
1.80
1.80
3.62
3.44
8.25
4.65
3.40
3.30
3.36
3.30
3.67
8.10
3.95
2.82
2.91
6.96
6.65
8.58
4.33
1.76
1.61
2.18
1.96
8.18
3.70
3.52
8.15
4.66
3.04
2.71
7.15-7.27
4.27
2.17
1.95
4.40
3.82
3.69
4.17
3.20
3.25-3.30
3.25-3.30
3.25-3.30
3.59
aAt the current stage of the research it was not possible to assign
neither hydroxyl chemical shifts nor Tyr NH3' chemical shifts except
for (3) in the latter case.
assigned by phase sensitive 2QF-COSY (Marion and
Wuthrich, 1983) and Relayed-COSY (Weber and Muller,
1987) experiments. All assignments are listed in Table I.
The 3JHN,X coupling constants were measured from ID
spectra and are given in Table II. 3J,o coupling constants
for Phe4 were also measured from ID spectra (see
Table V).
Amide chemical shifts, their temperature coefficients and
the 3JHNa coupling constants are listed in Table II. The
values are independent of concentration within experimental
error.
NOEs were measured using NOESY (Kumar et al., 1980)
and ROESY (Bothner-By et al., 1984) experiments. For
qualitative purposes ROESY was found to be better than
NOESY since more NOEs were detected. Some different
values of mixing times (Tm) were tested (50-200 ms). A
time of 100 ms was found to be optimal for (2), whereas
for (1) and (3) a Tm of 200 ms was used. ROESY data can
Table II. Chemical shifts, temperature coefficients and coupling
constants of the NH protons
Residue
D-Met2 Gly3 Phe4 galac6
6 (p p-m.) (1) 8.57 8.13 8.19
(2) 8.62 8.20 8.12 8.25
(3) 8.52 8.18 8.15
Ab/AT (1) -3.0 -3.0 -4.5
(p.p.b./K) (2) -2.5 -3.0 -4.5 -4.5
(3) -5.5 -8.5 -4.5
3JHNa (1) 7.9 5.8a 8.4
(Hz) (2) 7.8 6. la 8.4 9.1
(3) 7.9 5.7a 8.4
aBOth 3JHNa, measured were equal.
Table Im. Intrarresidual NOEs observed by ROESY in DMSO-d6
Correlationa Compound
(1) (2) (3)
Tyr NH3+-aH - - + +
Tyr NH3 -,H - - +
Tyr orthoH-axH ++ ++ ++
Tyr orthoH-,BH + + +
Tyr metaH-(3H - + +
Tyr caH-(-H + + +
D-Met NH-aH + + +
D-Met NH-f,BH +
D-Met NH-132H + ++ ++
D-Met NH- yH ++ ++ ++
D-Met alH-3,H ++ ++ ++
D-Met aH-(32H ++ ++ ++
D-MetaH-,yH ++ ++ +++
Gly NH-ajH D + + + -
Gly NH-a2H D2 +++ +++
Phe NH-caH + + +
Phe NH-,lIH ++
Phe NH-(32H + ++ ++
Phe aH-0,BH ++ ++ ++
Phe aH-,32H + ++ +
Pro aH-j-H ++ ++ ++
Pro -yH-AH ++ ++
Hyp
-yH-OH ++
galac NH-HI +
galac NH-H2 + +
aLetter correlates with ROESY cross-peaks in Figures 4 and 5 and
with short distances in Figure 6.
be found in Tables III (intrarresidual NOEs) and IV (inter-
residual NOEs).
Our proposal for the backbone conformation of (1), (2)
and (3) is based on (i) measurements of the 3JHN, coupling
constants, (ii) the occurrence of NOEs as measured by
ROESY and NOESY experiments and (iii) the solvent
exposure as revealed by the temperature dependence of the
NH chemical shifts.
Experimental data seem to be similar for both the
N-terminus and C-terminus of the three compounds in
contrast with the obtained parameters for Gly3.
DMet2 and Phe4 show 3JHNa values of -8 Hz, which
correspond to Xi torsion angles around -90° or - 150°
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(Phe4) and +900 or + 1500 (DMet2) when the equation:
JHN! -= 6.4 cos20 -1.4 cosO + 1.9,
with 0 = 10-6001 (L-AA) or 14+6001 (D-AA), is used
Table IV. Interresidual NOEs observed by ROESY in DMSO-d6
solutions
Correlationa Compound
(1) (2) (3)
303 K 333 K
caiH-NHi + I
Tyr aH-D-Met NH A +++ +4-++ +++ -
D-Met caH-Gly NH B +++ +++ +++ +
Gly aH-PheNH C1 +++ +++ - -
Gly a2H-PheNH C2 +++ +++ +++ +
Pro caH-galac NH ++
iH-NHi+,
Tyr ,H-D-Met NH + ++ +
CijH-bj+ 1H
Phe acH-Pro 61H + + + + + +
Phe aH -Pro 62H + + + + + +
Phe afH-Hyp 61H El +++ ++
Phe aH-Hyp 62H E2 +++ ++
Others
Hyp yH-galac HI F +++ ++
aLetters correlate with ROESY cross-peaks in Figures 3-5 and with
short distances in Figure 6.
(Pardi et al., 1984). Since in proteins (L-amino acids) +
angles of all residues except glycine have been reported to
be in the range -30° to -180° (Richardson, 1981), both
of the angles obtained for each amino acid are possible.
Nevertheless, the detection of the similarly intense NH- aH,
NH-f31H and NH-f2H ROESY cross-peaks both in
DMet2 and Phe4 leads to 4i angles around +1500 and
-150°, respectively, since 42 = +90° and 04 = -900
are not consistent with NH-aH NOEs (Sherman et al.,
1987). In addition, the strong TyrazH-DMetNH,
DMetaHH-GlyNH and either PheaHH-Prob lH and
PheaH -Prob2H or PheaH
-Hyp6IH and PheaH-Hyp62H
interresidual ROESY cross-peaks indicate that
1jz 4 z + 120° and 12 =- 1200 in the three compounds
and ProaH -galacNH NOE leads also to 65 =+ 1200 in (2)
(Billeter et al., 1982). The 4i and {i torsion angles obtained
are consistent with the existence of two fairly rigid
fl-structures involving on one hand Tyr' and DMet2 and on
the other hand Phe4 and Pro5, extended to the galactose
moiety in (2).
Following the Karplus equation given previously (Pardi
et al., 1984) and the Bystrov curves for glycyl residues
(Bystrov, 1976) the measured 3JHNa1Ia2 vicinal coupling
constants of Gly3, around 6 Hz, lead to 03= +300 or
-300 for the three compounds. These torsion angles are
consistent with the detection of NH- a H but not
NH-a2H NOEs, and NH-c2H but not NH-aIH,
respectively. The observation of both NOEs in (2) (ROESY
cross-peaks D1, D2 in Table III and Figure 4) is then
incompatible with the 3JHN, data and indicates confor-
mational heterogeneity. In contrast, only the NH-oa2H
0
B C2 Cl
I I
.
II I I I I I
4.8 4.6 4.4 4.2 4.0 3.8 3.6
PPM
p
_ 8.2
8.4
8.6
'PM
Fig. 3. ROESY spectrum of compound (1) in DMSO-d6. NH-CaH extensions where (A) Tyr caH-DMet NH; (B) DMet aiH-Gly NH; (Cl)
Gly aiH-Phe NH; (C2) Gly ca2H-Phe NH. 10 mM, 303 K, mixing time Tm = 200 ms. Negative levels are shown.
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NOE was detected in (3) (ROESY crosspeak D2 in Table
III and Figure 5) which accounts for the existence of only
one of those 03 possibilities. Which 43 corresponds to this
observation is not known without stereospecific assignment
of a IH and ca2H. As far as the {3 torsion angle is
concerned, the strong Glya2H-PheNH (ROESY cross-
peak C2 in Table IV and Figure 5) and the absence of the
Glya1HH-PheNH sequential ROESY cross peak in (3)
agree with i3 = + 120' or -120°. Again the lack of stereo-
specific assignment of a1H and a2H prevent a choice
between t3 values. Nevertheless, since GlyNH-aH and
GlyaH -PheNH NOEs detected involve the same GlycuH,
the only possible combinations for (03, 3) are
(+300, + 1200) and (-300,-120°). On the other hand, the
,.
a~~~~ 2
2
p3
C10
~DjX _
C2 .
Di
(° A , -4
B M
8.5PP
PPM
presence of two equally intense aHi
-NHi+I for (1)(ROESY cross-peaks C1, C2 in Table IV and Figure 3) and
(2) (ROESY cross peaks C1, C2 in Table IV and Figure 4)
corresponds to i3=00 which is energetically unfavourable.
Considering the conformational heterogeneity at Gly3, the
detection of NOEs involving both GlyaH is likely to be due
to the co-existence of conformations with different 1,t3. A
possible combination would involve both conformations
under consideration for (3).
Further restrictions can be introduced considering the
conformation of the Phe4 side-chain (Table V). The data
concerning compound (3) are consistent with a large
population of the gauche (-) rotamer. In such a case, the
conformation corresponding to 03 = +300 and 1,63 +1200
is clearly unfavourable and should be discarded. On the other
hand, the data corresponding to (1) and (2) are more
ambiguous. In that case, although &3 = + 1200 should be
also unfavourable, the consideration of all the significant
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Fig. 4. ROESY spectrum of compound (2) in DMSO-d6. NH-CaH
extensions where (A) Tyr cHH-DMet NH; (B) DMet aH -Gly NH;
(Cl) Gly a,H-Phe NH; (C2) Gly a2H-Phe NH; (D1) Gly
NH-ca1H; (D2) Gly NH-a2H. 10 mM, 303 K, mixing time Tm =
100 ms. Negative levels are shown.
_ i.5
2.0
- 2.5
- 3.0
- 3.5
- 4.0
- 4.5
8.5 8.0
PPM
Fig. 5. ROESY spectrum of compound (3) in DMSO-d6. NH-CaH
extensions where (A) Tyr cHH-DMet NH; (B) DMet aH-Gly NH;
(C2) Gly a2H-Phe NH; (D2) Gly NH-a2H. 20 mM, 303 K, mixing
time Tm = 200 ms. Negative levels are shown.
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Table V. Data determining Phe4 side-chain conformation
3'aJi 'Jai)2 NOEaH IH NOEaH-2H NOENH-IH NOENH-2H(Hz) (Hz)
(1) 4.3 9.1 ++ + - +
(2) - 8.8 ++ ++ ++ ++
(3)4.0 8.8 ++ + - ++
Fig. 6. Proposed conformnation for compound (3). Solid arrows, short
distances corresponding to intra-residual ROESY cross-peaks; broken
arrows, short distances corresponding to inter-residual ROESY cross-
peaks. Letters correlate with ROESY cross-peaks in Tables III and IV
and Figure 5.
NMR data obtained in the present work does not allow us
to discard any of the possible torsion angles.
In summary, the three compounds tested present two f
strands connected to each other by a fairly flexible glycyl
residue at position 3. For compounds (1) and (2), experi-
mental data are inconsistent with a single conformation of
Gly3. In contrast, compound (3) seems to preferentially
exist in a more rigid folded conformation in which
43 =-30 and t3 =-120 (Figure 6).
The temperature coefficients summarized in Table II show
no evidence for hydrogen bonds involving the amide protons.
Furthermore, other experimental evidence has led us to
suggest an explanation for the preferential existence of the
proposed folded conformation in the 3O-galactosyl analogue(3) and not in the (3N-galactosyl analogue (2). Three strong
NOEs detected even at 333 K, namely the previously
mentioned PheaH-Hyp6lH, PheaH-Hyp52H and
Hyp-yH-galacHl (ROESY cross peaks El, E2 and F,
respectively, in Table IV and Figure 5) prove that the
C-terminus of (3) is an especially rigid part of the molecule
compared with the N-terminus, since the rest of the sequen-
tial NOEs were weaker at high temperatures. In the proposed
conformation for compound (3) (Figure 6) the hydroxyl
groups in positions 4 and 6 of the galactosyl residue are faced
to the carbonyl groups of DMet2 and Gly3, respectively, so
we suggest that such a conformation could be stabilized by
hydrogen interactions between hydroxyl groups of galactose
and carbonyl groups of the peptide backbone. Unfortunately,
such a hypothesis cannot be supported by NOE data since
all the non-exchangeable hydrogens of the galactosyl residue
are too far from any hydrogen of the peptide moiety to show
an observable NOE.
Discussion
The experimental NMR data presented are consistent with
two fl-strands (N-terminus and C-terminus) connected to
each other by Gly3 for the three compounds tested. Both the
parent compound [DMet2,Pro5] enkephalin amide (1), and
the N" 5 galactosyl analogue [DMet2,Pro5] enkephalin[Nl 5-0-D-galactopyranosyl] amide (2) have been found to
exhibit a similar conformational equilibrium with great
flexibility at position 3. In contrast, O"5-(3-D-galacto-
pyranosyl) [DMet2,Hyp5] enkephalin amide (3) shows a
preferential folded structure.
As mentioned before, the N' 5-galactosyl derivative (2) is
significantly more potent than the parent compound (1) in
rats, in both the tail immersion and paw pressure tests of
analgesia after intraventricular administration. This
difference in the analgesic activity of (1) and (2) cannot be
related to any conformational change in DMSO solution since
all the significant NMR parameters measured are very
similar and consistent with a similar conformational
equilibrium. Nevertheless, the increase in the analgesic
activity of the O"5-galactosyl analogue (3) with respect to
the N 5-galactosyl analogue (2) could be related to the
adoption of the preferential folded conformation proposed
in this work.
In conclusion, the introduction of a galactosyl moiety into
the fifth residue of [DMet2,Pro5] enkephalinamide leads to
an increase in analgesic activity of - 100-times which is
independent of the conformation of the molecule in DMSO
solutions. Nevertheless, folded conformations seem to play
an additional important role. In fact, when the galactosyl
moiety is incorporated into another position in the same
residue which allows galactose-peptide backbone inter-
actions, a preferential folded conformation is detected. Such
a conformational change could be related to an extra
increment in analgesic activity of - 10 times.
Materials and methods
Synthesis
Thin layer chromatography was performed on silica gel plates (0.25 mm)
from Merck. Spots were detected by reaction with ninhydrin or chlorine
followed by tolidine solution. The sugar was detected by Orcinol -HCl.
Amino acid analysis was performed in a Beckman 119 C instrument or a
Biotronik LC 5001. All the solvents used were of analytical grade. They
were distilled and stored over molecular sieves when necessary.
Microanalyses were performed by the Microanalytical Laboratory,
Department of Biological Organic Chemistry, CID, Barcelona. FAB mass
spectra were determined with a MS9-V6 updated system equipped with a
VG- 11 250 data system by the Laboratory of Mass Spectrometry, CID,
Barcelona. An ion tech atom gun and a standard FAB source were used.
The samples, dissolved in glycerol, were bombarded with 8 keV xenon atoms
and the ions produced accelerated through 8 kV.
Isolation and purification of the protected glycosyl derivatives of the amino
acids and peptides was carried out by flash chromatography, using Silica
gel (40-63 Am), 15 x 2 or 15 x 5 cm columns eluted with the
appropriate solvent system at a flow rate of 5 cm/min.
The purity of the protected glycosyl amino acids and peptides was checked
by reversed-phase HPLC [ODS, 5 1tm column, H20 0.05% trifluoroacetic
acid (TFA):CH3CN gradient elution from 9 to 100% CH3CN at a linear
rate of 3.5% CH3CN/min] with detection by absorbance rationing
measurements at several wavelengths.
2,3,4,6-tetra-0-acetyl-jS-D-galactopyranosyl amine has been obtained
from acetobrome-D-galactose according to the Bertho et al. (1932)
procedure. The resulting product was characterized by 'H-NMR. Melting
point 137- 139°C (literature value = 139°).
Two different amino acid N-protecting groups have been used, benzyloxy-
carbonyl (Z) and tert-butyloxycarbonyl (tBoc). Z groups were cleaved by
hydrogenolysis in the presence of 10% palladium on charcoal (0.1g/g) in
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methanol. Removal of tBoc groups was achieved with TFA:CH2CI2 (1:1)
containing a few drops of 2-mercaptoethanol, 30 min at room temperature
with a ratio of 10 mnl acid -solvent mixture to 1 mmol of peptide or amino
acid derivatives.
All optically active amino acids were of the L configuration with the
exception of D-methionine, as indicated throughout the text.
'H-NMR characterization of the final derivatives is not included in this
experimental section.
/3N-glycosylation. Synthesis of Tyrosyl, D-methionyl, glycyl, phenylalanyl,
prolyl [N'-I3-D-galactopyranosyl] amide. Compound (2).
tBoc-Tyr-DMet-Gly-Phe-Pro-OH (0.750 g, 1.05 mmol) and
2,3,4,6-tetra-0-acetyl-,3-D-galactopyranosylamine (0.36 g, 1.05 mmol)
were dissolved in 20 ml of tetrahydrofuran (THF) at -200C. 1-hydroxy-
benzotriazol (HOBt) (0.15 g) and two drops of 2-mercaptoethanol were added
to the solution. N,N'-dicyclohexylcarbodiimide (DCC) (0.21 g, 1.05 mmol)
dissolved in 2 ml of THF was also added dropwise to the solution and the
reaction mixture was kept at -200 for 1 h and then overnight at room
temperature. The mixture was then filtered and the filtrate washed
successively with 5% citric acid (3 x 20 ml), 5% sodium bicarbonate
(3 x 20 ml) and water (3 x 20 ml). The organic layer was then dried over
anhydrous Na2SO4 and the amorphous solid obtained after evaporation was
purified by flash chromatography on silica gel using ethyl acetate:methanol
(8:2) as eluent. Amino acid analysis: Tyr 0.94, D-Met 0.91, Gly 1.00, Phe
0.97, Pro 0.99. [a]20295 = 7.580, [a]20255 = -26.060, [a]20240 =
-12.120, [a]20235 = _38.18° (c = 0.32, methanol). 13C-NMR (20 MHz)(CDCI3) 83.0 Cl galactose j3 anomer.
The cleavage of the protecting groups was carried out in two steps,
TFA:CH2Cl2 (1:1) treatment for the elimination of the N-terminal tBoc
group and NH3:MeOH treatment for the cleavage of the acetyl groups. The
resulting galactopyranosyl peptide was then purified by gel filtration on
Sephadex G-25 and by semipreparative HPLC, C18, solvent system
H20-0.05% TFA:CH3CN, isocratic mode elution 70:30, X = 280 nm.
Homogeneity was assessed by TLC and reversed-phase HPLC ODS 5 Jim
column, solvent system H20-0.05% TFA:CH3CN 1 ml/min, gradient
elution from 10 to 90% CH3CN at a linear rate of 3.5% CH3CN/min,
0.16 AUFS with detection by absorbance rationing measurements. Amino
acid analysis: Tyr 0.95, D-Met 0.90, Gly 1.00, Phe 0.98, Pro 0.99.
[a]20295 = 6.070, [a]20255 = 28.21°, [a]20240 = 68.210, [a]20235 =
-63.930 (c = 0.32, methanol). 'H-NMR ROESY, different intensity of
galac N-I and galac N-2 cross-peaks consistent with (3 anomer. FAB mass
spectrometry: m/z 775 (M + 1).
300-glycosylation. Synthesis of Tyrosyl, D-methionyl, glycyl, phenylalanyl,
[O-(3-D-galactopyranosyl] hydroxyprolinamide. Compound (3).
Z-Hyp-OMe (0.700 g, 2.5 mmol) was dissolved in 40 ml of dry benzene
and 40 ml of nitromethane and heated under anhydrous conditions until about
15 ml of solvent had distilled off. To this solution a double equivalent amount
of both 2,3,4,6-tetra-O-aCetyl-a-D-galactopyranosyl bromide (2.056 g) and
Hg(CN)2 (1.286 g) were added in three portions: half of the given amounts
at the beginning of the reaction and the rest in two equal portions after 2
and 3 h, respectively. The mixture was heated at 800C for a total time of
4 h. The solution was then cooled and diluted with ether (80 ml) and filtered
to eliminate the precipitated mercuric salts. The filtrate was then washed
with water, dried over Na2SO4 and evaporated. The oily resulting mixture
was submitted to flash chromatography on Silica gel (40-63 Am),
15 x 5 cm ID column eluted with hexane:ethyl acetate (3:7). 1H-NMR
(360 MHz, CDC13) d 4.35 Jl,2 = 7.5 Hz H-1 ( anomer.
After hydrogenolysis of the Z group, the incorporation of the resulting
01-(2,3,4,6-tetra-O-acetyl-(-D-galactopyranosyl) hydroxyproline methyl
ester to the tetwapeptide tBoc-Tyr-DMet-Gly-Phe-OH by the DCC/HOBt
method and the purification of resulting procted galactosylated pentapeptide
were carried out following the same procedure stated for compound (2).
The cleavage of the protecting groups and the C-terminal amide formation
were also carried out in two steps, TFA:CH2CI2 (1:1) treatment for
elimination of N-terminal tBoc group and NH3:MeOH (saturated at 0°C)
treatment for the cleavage of acetyl groups and terminal amide formation
from the methyl ester. The resulting galactopyranosyl peptide was then
purified by gel filtration on Sephadex G-25 and semipreparative HPLC,
C18, solvent system H20-0.05% TFA:CH3CN, isocratic mode elution
70:30, X =280 nm. Homogeneity was assessed by TLC and reversed-phase
HPLC ODS 5Fm column, solvent system H20--0.05% TFA:CH3CN
ml/min, gradient elution from 10 to 90% CH3CN at a linear rate of 3.5%
CH3CN min, 0.16 AUFS with detection by absorbance rationing
measurements. Amino acid analysis: Tyr 0.95, D-Met 0.90, Gly 1.00, Phe
1.05, Hyp 0.98. [a]20295 = 4.370, [a]20254 = 00, [a]20240 = 19.370,
[a]20235 = 9.690 (c = 0.32, MeOH). FAB mass spectrometry m/z 791
(M + 1), 813 (M + 23). 'H-NMR (270 MHz, DMSO-d6) 3Jl12 galac =
7.09, anomer.
The parent compound (1) has been synthesized by coupling tBoc-
Tyr-DMet-Gly-Phe-OH and H-Pro-OMe followed by deprotection and
terminal amide formation.
Epimerization has been checked by gas chromatography on an enantio-
selective stationary phase (cyano ethyl-siloxane-L-valine-S-c-phenyl ethyl
amide, Quirasil-valine). The extent of epimerization produced during each
step in the synthesis of compounds (1-3) was not greater than 1 %.
Conformational analysis
NMR spectra were recorded on a Bruker AM 270 spectrometer equipped
with an Aspect 2000 computer running the DISN861 program. The obtained
data were also processed with an Aspect 3000 computer running DISR87
or DISR88. For the conformational study the sample concentration was 10
or 20 mM in DMSO-d6 (CEA 99.98%). Samples were degassed by several
freeze-pump-thaw cycles. The types of 2D-NMR experiments carried
out were phase-sensitive, double quantum filtered COSY (Marion and
Wuithrich, 1983) and relayed COSY (Weber and Muller, 1987), NOESY
(Kumar et al., 1980) and ROESY (Bothner-By et al., 1984).
All spectra were measured with a spectral width of 2703 Hz, covering
the range 0.0-10.0 p.p.m.
The ID spectra were measured with 8 K data. The interferograms were
multiplied by a Gaussian function with LB = -3 and GB = 0.3, zero-
filled to 16 K and Fourier transformed. The resulting spectra had a digital
resolution of 0.3 Hz/point.
All the 2D spectra were measured in a phase-sensitive mode using TPPI
(Marion and Wuthrich, 1983). In relayed COSY, the relay period amounted
to 50 ms. Mixing times were 200-400 ms in NOESY and 50-200 ms
in ROESY. In ROESY experiments the spin-lock field was 3.8 kHz, to
minimize Hartman-Hahn effects (Bax and Davies, 1985).
All 2D spectra consisted of 256 or 512 interferograms of 1 K data. The
interferograms were multiplied by a Gaussian function with LB = -3 and
GB = 0.3 and Fourier transformed. The t1-interferograms were multiplied
by a sine bell function shifted by 7r/8, zero-filled to 1 K and Fourier
transformed. The digital resolution in the resulting 512 x 512 W spectra
was 5.3 Hz in both dimensions.
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